-NeoB not checked

Advanced Accelerator Applications · AAA603

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Neoplasms
Main trialPhase 1/2
“First in Human (FIH) study to characterize the safety, tolerability, pharmacokinetics (PK), distribution, radiation dosimetry, and anti-tumor activity of \[177Lu\]-NeoB in patients with advanced solid tumors known to overexpress GRPR and with \[68Ga\]-NeoB lesion uptake.”In the company’s words, NCT03872778 on ClinicalTrials.gov
Other names
Lutetium NeoB · AAA603 · Gallium NeoB

Other drugs for Neoplasms

All 2439 drugs for Neoplasms

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Completed 7 Jan 2025 [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow -NeoB

Following is part of Solo: you see every change to -NeoB the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in